A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
← catalyst calendarNCT06465329 · readout in 274 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
120estimated
Sites
50
Countries
Brazil, France, Germany +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-11-18 | actual | When the study began enrolling |
| Primary completion | 2027-05-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-05-02 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-08 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Non-Small Cell Lung Cancer
Interventions
- Drug: Cemiplimab — also filed as REGN2810, LIBTAYO
- Drug: Platinum-based chemotherapy
- Drug: REGN7075 — also filed as EGFRxCD28 bispecific immunotherapy
Primary outcome
what the primary-completion date above is the date OFMajor pathologic response (MPR) rate as determined by central blinded independent pathology review (BIPR)
measured Up to 12 weeks
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed